Hospital Groups Cite Supreme Court Decision in Latest Briefs Backing Feds in Lilly and AstraZeneca 340B Cases

digital image of a courtroom
Hospital groups urged two federal appeals court to back the government in its fight to force Lilly and AstraZeneca to end restrictions on 340B pricing when covered entities use contract pharmacies.

Five groups that represent 340B hospitals have filed briefs in two federal appeals courts backing the federal government in its fight to force drug manufacturers Eli Lilly and AstraZeneca to end restrictions on 340B drug discounts when covered entities use

Read More »

Castle Family Health Centers Supports Excellence in Its 340B Program

SPONSORED CONTENT

For 340B covered entities, delivering quality care and providing access to services is critical for the wellbeing of the underserved patient populations in their communities.

When Castle Family Health Centers, a community health center in Merced County California with three locations, sought a partner to support the ongoing performance of their 340B program, their leadership looked for one who shared in

Read More »

Drug Makers’ 340B Overcharging Must Be Addressed, House E&C Democrat Dingell Says During Hearing

Rep. Debbie Dingell (D-MI) headshot
Drug manufacturers’ conditions on 340B pricing when covered entities use contract pharmacies “need to be addressed moving forward,” U.S. Rep. Debbie Dingell (D-Mich.) said during a recent hearing.

Drug manufacturers’ decisions to impose conditions on 340B pricing when covered entities use contract pharmacies “need to be addressed moving forward,” U.S. Rep. Debbie Dingell (D-Mich.) said last week during an Energy & Commerce (E&C) health subcommittee hearing last week.

Read More »

Lilly Announces Fourth Round of Refunds for 340B Overcharges in 2019

Lilly wordmark building-mounted sign
Lilly for the fourth time this year has announced refunds for overcharges on 340B-purchased drugs during 2019.

For the fourth time this year, drug manufacturer Lilly has announced refunds for overcharges on 340B-purchased drugs during 2019.

The U.S. Health Resources and Services Administration (HRSA) posted the notice, dated May 27, on the Office of Pharmacy Affairs website

Read More »

Novo Nordisk, Sanofi, and Feds Trade Arguments in 340B Contract Pharmacy Litigation

Federal Appeals Court courtroom interior
Novo Nordisk and Sanofi urged a federal appeals court in Philadelphia to reverse a district judge’s ruling that their denials on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.

Drug manufacturers Novo Nordisk and Sanofi last month urged a federal appeals court to reverse a district judge’s ruling that the companies’ conditions on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.

Meanwhile, the federal government

Read More »

340B Sales Were $38.8 Billion in 2020, PhRMA-Funded Study Finds

Image of BRG 340B program white paper title page
Prescription drugs sales at 340B prices were $38.8 billion in 2020, a new PhRMA-funded study says.

Prescription drugs sales at 340B prices were $38.8 billion in 2020, “more than three times the level of 340B sales compared to just five years prior,” new drug industry funded research shows.

Total sales would have been $93.6 billion if

Read More »

Meet AIDS Healthcare Foundation Pharmacist, and Artist, Alsean Bryant

Alsean Bryant portrait on a red background

SPONSORED CONTENT

The 340B drug pricing program enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. But 340B’s benefit goes beyond providing office visits with a physician and prescriptions to control HIV. 340B also supports the execution of many pharmacy support services. One is AIDS Healthcare Foundation’s Strategic Response Team

Read More »

Breaking News

In Important Ruling, Federal Appeals Court Says Health Center May Challenge 340B Patient Definition’s Legality

Genesis Health Care exterior sign and building
A federal appeals court says South Carolina health center Genesis Healthcare has the right to challenge the 340B patient definition's legality in a lower federal court.

A federal appeals court ruled unanimously this morning that a South Carolina health center has the right to challenge the legality of the government’s 340B patient definition in a lower federal court. The case ultimately could have profound implications for

Read More »

Breaking News

Bausch Health Announces 340B Contract Pharmacy Restrictions on All Covered Entities

Bausch Health wordmark seen through eyeglass lens
Bausch Health has imposed conditions on 340B pricing when all covered entity types—hospitals and grantees alike—use contract pharmacies.

Bausch Health this afternoon became the 18th drug manufacturer to impose conditions on 340B pricing when covered entities use contract pharmacies. The restrictions apply to all entities; there is no exemption for federal grantees.

According to Bausch’s announcement, effective Aug.

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report